Sarepta Therapeutics, Inc.
SRPT · XNASCIK 873303fmd_1XJCV5MA48G0PV2TJWS5GNJC5RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 155 | 301 | 381 | 540 | 702 | 933 | 1,243 | 1,902 | 2,198 |
| Cost of revenue | 0 | – | – | – | – | – | – | – | – | 26 |
| Gross profit | 5 | – | – | – | – | – | – | – | – | 2,173 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | 2 | (3) | (16) |
| Research and development | 188 | 167 | 402 | 561 | 722 | 771 | 877 | 877 | 805 | 1,522 |
| Selling, general and administrative | 84 | 123 | 208 | 285 | 318 | 283 | 451 | 482 | 558 | 492 |
| Impairment of real estate | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Operating income | (267) | (172) | (344) | (706) | (564) | (460) | (536) | (268) | 218 | (700) |
| Interest expense | 2 | 6 | 34 | 31 | 60 | 64 | (53) | (22) | (18) | (38) |
| Interest and investment income | 1 | 2 | 7 | 7 | 3 | 0 | 16 | 36 | 31 | 31 |
| Other non-operating income (expense) | (1) | 123 | (19) | (8) | 11 | 41 | (154) | (252) | 43 | (2) |
| Income before taxes | (267) | (49) | (363) | (714) | (553) | (419) | (690) | (520) | 261 | (702) |
| Income tax expense | – | 2 | (1) | 1 | 1 | (0) | 14 | 16 | 26 | 11 |
| Net income from continuing operations | – | (51) | (362) | (715) | (554) | (419) | (703) | (536) | 235 | (713) |
| Net income | (267) | (51) | (362) | (715) | (554) | (419) | (703) | (536) | 235 | (713) |
| Net income to common shareholders | – | – | – | – | – | – | (703) | (536) | 235 | (713) |